NovaBridge Biosciences
NBP
$2.97
$0.072.41%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
3/16/2026
-
MarketBeat
3/16/2026
-
TipRanks Financial Blog
3/16/2026
-
TipRanks Financial Blog
3/16/2026
-
Globe Newswire
3/11/2026
-
Tickeron - Stocks
3/9/2026
-
SeekingAlpha
3/9/2026
-
Seeking Alpha: Transcripts
3/9/2026
-
TipRanks Financial Blog
3/9/2026
-
Benzinga
3/9/2026
-
Globe Newswire
3/7/2026
-
Tickeron - Technical Analysis
3/6/2026
-
Tickeron - Stocks
3/5/2026
-
Tickeron - Stocks
NovaBridge Biosciences (NBP, $3.11) price may climb as it broke lower Bollinger Band on Mar 04, 2026
3/5/2026
-
Tickeron - Stocks
3/4/2026
-
Tickeron - Stocks
3/4/2026
-
Tickeron - Stocks
3/3/2026
-
TipRanks Financial Blog
3/3/2026
-
Globe Newswire
3/3/2026
-
Tickeron - Stocks
3/3/2026
-
MarketBeat
3/2/2026
-
Globe Newswire
2/28/2026
-
Tickeron - Stocks
2/20/2026
-
Tickeron - Stocks
2/19/2026
-
Globe Newswire
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
--
Net Income (TTM)
--
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
--
Cash from Investing (TTM)
--
Cash from Financing (TTM)
--
Net Change in Cash (TTM)
--
Filings
Filing Date
Thursday, December 18, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Beginning of April (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
240 745 6330
Address
2440 Research Boulevard
Rockville, MD 20850
Rockville, MD 20850
Country
Year Founded
Business Description
Sector
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a...
more